Literature DB >> 26826887

How robust is ACTIVLIM for the follow-up of activity limitations in patients with neuromuscular diseases?

Charles Sèbiyo Batcho1, Peter Y K Van den Bergh2, Philip Van Damme3, Anna J Roy4, Jean-Louis Thonnard5, Massimo Penta6.   

Abstract

This study aims to investigate the clinimetric properties of ACTIVLIM, a measure of activity limitations, when it is used in daily practice in a large nationwide representative cohort of patients with neuromuscular diseases. A cohort of 2986 patients was assessed at least once over 2 years in 6 national neuromuscular diseases reference centers. Successive Rasch analyses were conducted in order to investigate the scale validity, reliability, consistency across demographic and clinical sub-groups and its sensitivity to change. ACTIVLIM confirmed excellent fit to a unidimensional scale, with stable but 3-times more accurate item calibrations compared to the original publication. It showed a good reliability (R = 0.95), an appropriate targeting for 87% of the sample and an excellent invariance across age, gender, language and time. Despite some variations in the item difficulty hierarchy across diagnoses, ACTIVLIM exhibited a good capability to quantify small but significant changes in activity for various diagnostic groups. Overall, ACTIVLIM demonstrated very good clinimetric properties, allowing accurate quantitative measurement of activity limitations in both children and adults with a variety of neuromuscular diseases.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Activity limitations; Neuromuscular diseases; Patient-reported outcome measure; Rasch analysis

Mesh:

Year:  2015        PMID: 26826887     DOI: 10.1016/j.nmd.2015.12.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

1.  Assessment of disease progression in dysferlinopathy: A 1-year cohort study.

Authors:  Ursula Moore; Marni Jacobs; Meredith K James; Anna G Mayhew; Roberto Fernandez-Torron; Jia Feng; Avital Cnaan; Michelle Eagle; Karen Bettinson; Laura E Rufibach; Robert Muni Lofra; Andrew M Blamire; Pierre G Carlier; Plavi Mittal; Linda Pax Lowes; Lindsay Alfano; Kristy Rose; Tina Duong; Katherine M Berry; Elena Montiel-Morillo; Irene Pedrosa-Hernández; Scott Holsten; Mohammed Sanjak; Ai Ashida; Chikako Sakamoto; Takayuki Tateishi; Hiroyuki Yajima; Aurélie Canal; Gwenn Ollivier; Valerie Decostre; Juan Bosco Mendez; Nieves Sánchez-Aguilera Praxedes; Simone Thiele; Catherine Siener; Jeanine Shierbecker; Julaine M Florence; Bruno Vandevelde; Brittney DeWolf; Meghan Hutchence; Richard Gee; Juliana Prügel; Elke Maron; Heather Hilsden; Hanns Lochmüller; Ulrike Grieben; Simone Spuler; Carolina Tesi Rocha; John W Day; Kristi J Jones; Diana X Bharucha-Goebel; Emmanuelle Salort-Campana; Matthew Harms; Alan Pestronk; Sabine Krause; Olivia Schreiber-Katz; Maggie C Walter; Carmen Paradas; Jean-Yves Hogrel; Tanya Stojkovic; Shin'ichi Takeda; Madoka Mori-Yoshimura; Elena Bravver; Susan Sparks; Jordi Díaz-Manera; Luca Bello; Claudio Semplicini; Elena Pegoraro; Jerry R Mendell; Kate Bushby; Volker Straub
Journal:  Neurology       Date:  2019-01-09       Impact factor: 9.910

Review 2.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

3.  Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach.

Authors:  Anna G Mayhew; Meredith K James; Ursula Moore; Helen Sutherland; Marni Jacobs; Jia Feng; Linda Pax Lowes; Lindsay N Alfano; Robert Muni Lofra; Laura E Rufibach; Kristy Rose; Tina Duong; Luca Bello; Irene Pedrosa-Hernández; Scott Holsten; Chikako Sakamoto; Aurélie Canal; Nieves Sánchez-Aguilera Práxedes; Simone Thiele; Catherine Siener; Bruno Vandevelde; Brittney DeWolf; Elke Maron; Heather Gordish-Dressman; Heather Hilsden; Michela Guglieri; Jean-Yves Hogrel; Andrew M Blamire; Pierre G Carlier; Simone Spuler; John W Day; Kristi J Jones; Diana X Bharucha-Goebel; Emmanuelle Salort-Campana; Alan Pestronk; Maggie C Walter; Carmen Paradas; Tanya Stojkovic; Madoka Mori-Yoshimura; Elena Bravver; Jordi Díaz-Manera; Elena Pegoraro; Jerry R Mendell; Volker Straub
Journal:  Front Neurol       Date:  2022-03-10       Impact factor: 4.003

4.  Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months.

Authors:  Bram De Wel; Maxim De Schaepdryver; Koen Poesen; Kristl G Claeys
Journal:  Ann Clin Transl Neurol       Date:  2022-07-14       Impact factor: 5.430

5.  Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

Authors:  P Vanherpe; S Fieuws; A D'Hondt; C Bleyenheuft; P Demaerel; J De Bleecker; P Van den Bergh; J Baets; G Remiche; K Verhoeven; S Delstanche; M Toussaint; B Buyse; P Van Damme; C E Depuydt; K G Claeys
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.